Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has issued a warning letter to Hospira, a global injectable drugs and infusion technologies provider, over drugs contamination at its manufacturing plant in India.
Subscribe to our email newsletter
In October 2012, the facility in Tamil Nadu was inspected and was found to have been breaching quality regulations during drugs manufacturing, as reported by Reuters.
The regulator also raised issues relating to sanitization, sterilisation and contamination for finalised products.
Hospira has been involved in many regulatory problems relating to its manufacturing facilities for the past three years and was banned in February 2013 by the FDA from importing certain products, as reported by the news agency.